Results 21 to 30 of about 2,782 (157)

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. [PDF]

Diabetes Obes Metab
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing.
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E.   +8 more
europepmc   +3 more sources

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. [PDF]

Mol Metab
Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.In vitro assays were performed in cell lines selectively expressing rat or human amylin 1 receptor (AMY1R), amylin 3 receptor (AMY3R), or calcitonin receptor (CTR). In vivo studies were conducted in rats
Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T, Long A, Allen D, O'Farrell L, Bowen B, Pratt E, Tidemann-Miller B, Tham LS, Ibriga H, Alsina-Fernandez J, Mather KJ, Haupt A, Bhattachar SN.   +17 more
europepmc   +3 more sources

An amylin and calcitonin receptor agonist modulates alcohol behaviors by acting on reward-related areas in the brain

Progress in Neurobiology, 2021
Alcohol causes stimulatory behavioral responses by activating reward-processing brain areas including the laterodorsal (LDTg) and ventral tegmental areas (VTA) and the nucleus accumbens (NAc). Systemic administration of the amylin and calcitonin receptor agonist salmon calcitonin (sCT) attenuates alcohol-mediated behaviors, but the brain sites involved
Kalafateli AL, Satir TM, Vallöf D, Zetterberg H, Jerlhag E   +4 more
openaire   +4 more sources

An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side

Frontiers in Neuroscience, 2021
There is a substantial need for new pharmacological treatments of addiction, and appetite-regulatory peptides are implied as possible candidates. Appetite regulation is complex and involves anorexigenic hormones such as glucagon-like peptide-1 (GLP-1 ...
Olesya T. Shevchouk, Maximilian Tufvesson-Alm, Elisabet Jerlhag   +2 more
doaj   +1 more source

AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY [PDF]

Journal of IMAB
Amylin is a peptide hormone co-synthesized with insulin in pancreatic beta cells at a ratio of 1:100. Notably, amylin has a pronounced tendency to form toxic amyloid fibrils, a characteristic relevant to its pathological role.
Nikolinka Koleva, Boris Dinkov, Galya Stavreva   +2 more
doaj   +1 more source

Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options

Molecules, 2023
Obesity and type 2 diabetes (T2DM) are major public health concerns associated with serious morbidity and increased mortality. Both obesity and T2DM are strongly associated with adiposopathy, a term that describes the pathophysiological changes of the ...
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, Giulio Vistoli, Laura Fumagalli   +4 more
doaj   +1 more source

Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats

American Journal of Physiology-Endocrinology and Metabolism, 2023
These studies describe the beneficial effects of using a dual amylin and calcitonin receptor agonist (DACRA) for diabetes-related kidney complications. DACRA treatment reduced levels of serological biomarkers associated with kidney fibrosis. These reductions were further reflected by reduced collagen expression in diabetic kidneys.
Simone Anna Melander, Alexandra Louise Møller, Khaled Elhady Mohamed, Daniel Guldager Kring Rasmussen, Federica Genovese, Morten Asser Karsdal, Kim Henriksen, Anna Thorsø Larsen   +7 more
openaire   +4 more sources

Structure-based insight into development of selective and non-selective amylin and calcitonin receptor agonists

, 2022
Abstract Targeting amylin (Amy) receptors (AMYRs) can reduce body weight with additional benefits to other anti-obesity treatments such as glucagon-like peptide-1 receptor (GLP-1R) agonists. AMYRs are heterodimers of the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins (RAMPs), yielding AMY1R, AMY2R and AMY3R ...
Jianjun Cao, Matthew Belousoff, Radostin Danev, Madeleine Fletcher, Emma dal Maso, Herman Schreuder, Katrin Lorenz, Andreas Evers, Garima Tiwari, Melissa Besenius, Ziyu Li, Rachel Johnson, Denise Wootten, Patrick M. Sexton   +13 more
openaire   +1 more source

Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model

Menopause, 2021
Abstract Objectives: Menopause is often characterized by detrimental metabolic changes, such as obesity, insulin resistance, and impaired glucose tolerance, often requiring treatment. KeyBioscience Peptides (KBPs) are Dual Amylin and Calcitonin Receptor Agonists which have shown promising metabolic effects in rats ...
Katri, Anna, Reker, Ditte, Karsdal, Morten A., Bay-Jensen, Anne-Christine, Henriksen, Kim   +4 more
openaire   +3 more sources

KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats

Molecular Metabolism, 2021
Objective: Dual amylin and calcitonin receptor agonists (DACRAs) are novel therapeutic agents that not only improve insulin sensitivity but also work as an adjunct to established T2DM therapies.
K.V. Andreassen, A.T. Larsen, N. Sonne, K.E. Mohamed, M.A. Karsdal, K. Henriksen   +5 more
doaj   +1 more source